Drug discovery for epigenetics targets

Area of Science:

• Biochemistry
• Pharmacology
• Genetics

Background:

• Epigenetic dysregulation is implicated in major diseases, including cancer, autoimmune, cardiovascular, and neurological disorders.
• Epigenetic proteins (readers, writers, erasers) are druggable targets for small-molecule inhibitors.
• The reversible nature of epigenetic modifications makes pharmacological intervention an attractive therapeutic strategy.

Purpose of the Study:

• To provide an overview of epigenetics drug targets.
• To focus on approaches for initial hit identification in drug discovery.
• To describe the role of structure-guided chemistry in optimizing drug candidates and highlight challenges and future potential for epigenetics-based therapies.

Main Methods:

• Literature review of epigenetics drug targets and development strategies.
• Analysis of approaches for initial hit identification.
• Discussion of structure-guided chemistry optimization for clinical candidates.

Main Results:

• Epigenetic drug targets are viable for therapeutic intervention across various diseases.
• Small-molecule inhibitors targeting epigenetic proteins are a key focus in drug development.
• Structure-guided chemistry plays a crucial role in advancing initial hits to clinical candidates.

Conclusions:

• Epigenetics-based therapies represent a significant and evolving area in pharmaceutical research.
• Continued research into epigenetic drug targets and development pathways holds substantial promise for treating complex diseases.
• Overcoming current challenges is essential for realizing the full potential of epigenetics-based treatments.